-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga·05/19/2025 12:09:34
Listen to the news

Gainers

  • Healthcare Triangle (NASDAQ:HCTI) stock increased by 110.1% to $0.02 during Monday's pre-market session.
  • Protagenic Therapeutics (NASDAQ:PTIX) stock rose 78.48% to $5.41. The market value of their outstanding shares is at $2.9 million. The company's, Q1 earnings came out 4 days ago.
  • Brainstorm Cell (NASDAQ:BCLI) stock rose 41.66% to $1.87. The company's market cap stands at $10.6 million. As per the news, the Q1 earnings report came out 2 days ago.
  • Polyrizon (NASDAQ:PLRZ) stock increased by 34.84% to $0.01.
  • Armata Pharmaceuticals (AMEX:ARMP) stock increased by 32.59% to $1.79. The company's market cap stands at $64.7 million. The company's, Q1 earnings came out 3 days ago.
  • China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 25.04% to $1.5. The market value of their outstanding shares is at $20.6 million.

Losers

  • Mainz Biomed (NASDAQ:MYNZ) shares decreased by 17.6% to $2.01 during Monday's pre-market session. The market value of their outstanding shares is at $4.4 million.
  • Forte Biosciences (NASDAQ:FBRX) stock fell 14.78% to $6.69. The market value of their outstanding shares is at $44.0 million. The company's, Q1 earnings came out 2 days ago.
  • I-MAB (NASDAQ:IMAB) stock fell 11.12% to $0.8. The company's market cap stands at $64.7 million. The company's, H1 earnings came out 2 days ago.
  • Sharps Technology (NASDAQ:STSS) shares decreased by 10.51% to $4.09. The market value of their outstanding shares is at $22.4 million. The company's, Q1 earnings came out 2 days ago.
  • Lipocine (NASDAQ:LPCN) stock fell 8.78% to $3.64. The market value of their outstanding shares is at $19.4 million.
  • Klotho Neurosciences (NASDAQ:KLTO) stock decreased by 7.89% to $0.21. The company's market cap stands at $5.8 million. As per the news, the Q1 earnings report came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.